FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2120760124> ?p ?o ?g. }

• W2120760124 endingPage "1325" @default.
• W2120760124 startingPage "1319" @default.
• W2120760124 abstract "Based on the in vitro and in vivo potentiation of the cytotoxic activity of chemotherapeutic agents by the interferons, a pilot study combining human recombinant alpha-2b interferon (IFN) and doxorubicin was conducted for the treatment of unresectable, histologically proven hepatocellular carcinoma. Between March 1988 and May 1990, 21 patients (median age: 60 years, range: 29-76) entered the study. The dose of doxorubicin was fixed at 35 mg/m2, every 3 weeks. The dose of alpha-2b IFN was 6 million U/m2 per day, 5 days a week. 3 patients (14%) obtained a partial response lasting 11, 16 and 30 months, and 1 had a stable disease during 8 months. The other 17 patients died within a median survival time of 4 months. All patients experienced flu-like symptoms. 7 patients experienced WHO grade III-IV haematological toxicity. We conclude that the association of alpha-2b IFN and doxorubicin is feasible, with respect to the use of doxorubicin at an inferior dose level than the same agent used without IFN. The response rate is comparable to that observed with doxorubicin used alone. Further phase I studies and randomised trials are required to confirm the role of this regimen in the treatment of unresectable hepatocellular carcinoma." @default.
• W2120760124 created "2016-06-24" @default.
• W2120760124 creator A5006379192 @default.
• W2120760124 creator A5012098428 @default.
• W2120760124 creator A5012976258 @default.
• W2120760124 creator A5023530877 @default.
• W2120760124 creator A5023723238 @default.
• W2120760124 creator A5034192091 @default.
• W2120760124 creator A5041739182 @default.
• W2120760124 creator A5056078126 @default.
• W2120760124 creator A5056607327 @default.
• W2120760124 creator A5057307093 @default.
• W2120760124 creator A5061303106 @default.
• W2120760124 creator A5062080178 @default.
• W2120760124 creator A5078085733 @default.
• W2120760124 creator A5079480540 @default.
• W2120760124 date "1994-01-01" @default.
• W2120760124 modified "2023-10-03" @default.
• W2120760124 title "Treatment of unresectable hepatocellular carcinoma with a combination of human recombinant α-2b interferon and doxorubicin: Results of a pilot study" @default.
• W2120760124 cites W1929485758 @default.
• W2120760124 cites W1937560614 @default.
• W2120760124 cites W1965057891 @default.
• W2120760124 cites W1965726515 @default.
• W2120760124 cites W1967715111 @default.
• W2120760124 cites W1984925262 @default.
• W2120760124 cites W1995578078 @default.
• W2120760124 cites W1996549520 @default.
• W2120760124 cites W2018966838 @default.
• W2120760124 cites W2027809449 @default.
• W2120760124 cites W2045430314 @default.
• W2120760124 cites W2060441546 @default.
• W2120760124 cites W2062717712 @default.
• W2120760124 cites W2069576465 @default.
• W2120760124 cites W2075607397 @default.
• W2120760124 cites W2084460882 @default.
• W2120760124 cites W2085664147 @default.
• W2120760124 cites W2090686528 @default.
• W2120760124 cites W2167805334 @default.
• W2120760124 cites W4241231121 @default.
• W2120760124 cites W4246629919 @default.
• W2120760124 doi "https://doi.org/10.1016/0959-8049(94)90181-3" @default.
• W2120760124 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/7528030" @default.
• W2120760124 hasPublicationYear "1994" @default.
• W2120760124 type Work @default.
• W2120760124 sameAs 2120760124 @default.
• W2120760124 citedByCount "5" @default.
• W2120760124 crossrefType "journal-article" @default.
• W2120760124 hasAuthorship W2120760124A5006379192 @default.
• W2120760124 hasAuthorship W2120760124A5012098428 @default.
• W2120760124 hasAuthorship W2120760124A5012976258 @default.
• W2120760124 hasAuthorship W2120760124A5023530877 @default.
• W2120760124 hasAuthorship W2120760124A5023723238 @default.
• W2120760124 hasAuthorship W2120760124A5034192091 @default.
• W2120760124 hasAuthorship W2120760124A5041739182 @default.
• W2120760124 hasAuthorship W2120760124A5056078126 @default.
• W2120760124 hasAuthorship W2120760124A5056607327 @default.
• W2120760124 hasAuthorship W2120760124A5057307093 @default.
• W2120760124 hasAuthorship W2120760124A5061303106 @default.
• W2120760124 hasAuthorship W2120760124A5062080178 @default.
• W2120760124 hasAuthorship W2120760124A5078085733 @default.
• W2120760124 hasAuthorship W2120760124A5079480540 @default.
• W2120760124 hasConcept C126322002 @default.
• W2120760124 hasConcept C141071460 @default.
• W2120760124 hasConcept C143998085 @default.
• W2120760124 hasConcept C150903083 @default.
• W2120760124 hasConcept C203014093 @default.
• W2120760124 hasConcept C207001950 @default.
• W2120760124 hasConcept C2776178377 @default.
• W2120760124 hasConcept C2776694085 @default.
• W2120760124 hasConcept C2778019345 @default.
• W2120760124 hasConcept C2781228144 @default.
• W2120760124 hasConcept C2781303535 @default.
• W2120760124 hasConcept C2781413609 @default.
• W2120760124 hasConcept C2909179924 @default.
• W2120760124 hasConcept C29730261 @default.
• W2120760124 hasConcept C71924100 @default.
• W2120760124 hasConcept C86803240 @default.
• W2120760124 hasConcept C90924648 @default.
• W2120760124 hasConcept C98274493 @default.
• W2120760124 hasConceptScore W2120760124C126322002 @default.
• W2120760124 hasConceptScore W2120760124C141071460 @default.
• W2120760124 hasConceptScore W2120760124C143998085 @default.
• W2120760124 hasConceptScore W2120760124C150903083 @default.
• W2120760124 hasConceptScore W2120760124C203014093 @default.
• W2120760124 hasConceptScore W2120760124C207001950 @default.
• W2120760124 hasConceptScore W2120760124C2776178377 @default.
• W2120760124 hasConceptScore W2120760124C2776694085 @default.
• W2120760124 hasConceptScore W2120760124C2778019345 @default.
• W2120760124 hasConceptScore W2120760124C2781228144 @default.
• W2120760124 hasConceptScore W2120760124C2781303535 @default.
• W2120760124 hasConceptScore W2120760124C2781413609 @default.
• W2120760124 hasConceptScore W2120760124C2909179924 @default.
• W2120760124 hasConceptScore W2120760124C29730261 @default.
• W2120760124 hasConceptScore W2120760124C71924100 @default.
• W2120760124 hasConceptScore W2120760124C86803240 @default.
• W2120760124 hasConceptScore W2120760124C90924648 @default.
• W2120760124 hasConceptScore W2120760124C98274493 @default.
• W2120760124 hasIssue "9" @default.

• next